Showing results (101-110 of 156) with videos related to
Sort By:
Pageof 16
The Lancet. Oncology|November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trialFrancesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.Critical Reviews in Oncology/Hematology|November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trialsMattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.Cancer|September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patientsAlessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaAntonio Palumbo, Francesca Gay, Federica Cavallo, et al.Cancer Medicine|April 1, 2024
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experienceAnna Furlan, Michele Cea, Laura Pavan, et al.Bone Marrow Transplantation|June 24, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remissionDaniele Avenoso, Vera Radici, Alessandro Leoni, et al.Leukemia|May 23, 2021
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMTNicolaus Kröger, Giulia Sbianchi, Tiarlan Sirait, et al.Transplantation and Cellular Therapy|November 6, 2024
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic TransplantationChiara Nozzoli, Martina Pucillo, Luisa Giaccone, et al.The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.Pageof 16